Literature DB >> 11353570

Resistant hypertension and the Birmingham Hypertension Square.

D C Felmeden1, G Y Lip.   

Abstract

Recent guidelines for the treatment of hypertension place great emphasis on tighter blood pressure control, especially in the presence of hypertensive target organ damage and diabetes. In order to achieve these treatment targets, more patients will require a combination of antihypertensive medications. However, resistant hypertension may have many possible underlying causes, and clinicians should appreciate how to detect and tackle these potential problems. Effective and synergistic combinations are therefore of vital importance, especially in patients with resistant hypertension. The choice of rational first- and second-line drugs that act in synergy could lead to better blood pressure management as well as significant financial savings for health care resources. The use of the Birmingham Hypertension Square for the optimum choice of add-in drugs for the treatment of resistant hypertension may aid management.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11353570     DOI: 10.1007/s11906-001-0039-1

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  52 in total

Review 1.  Plasma angiotensin II and the antihypertensive action of angiotensin-converting enzyme inhibition.

Authors:  J Nussberger; B Waeber; H R Brunner
Journal:  Am J Hypertens       Date:  1989-04       Impact factor: 2.689

2.  Lack of effect of a diuretic added to diltiazem.

Authors:  G A MacGregor; F P Cappuccio
Journal:  J Hum Hypertens       Date:  1997-04       Impact factor: 3.012

3.  Prevalence of primary and secondary hypertension.

Authors:  L Wilhelmsen; G Berglund
Journal:  Am Heart J       Date:  1977-11       Impact factor: 4.749

4.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

5.  The influence of antihypertensive treatment over the incidence of cerebral vascular disease.

Authors:  D G Beevers; M Hamilton; M J Fairman; J E Harpur
Journal:  Postgrad Med J       Date:  1973-12       Impact factor: 2.401

6.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

7.  Comparison of nifedipine, prazosin and hydralazine added to treatment of hypertensive patients uncontrolled by thiazide diuretic plus beta-blocker.

Authors:  L E Ramsay; L Parnell; P C Waller
Journal:  Postgrad Med J       Date:  1987-02       Impact factor: 2.401

8.  Sustained antihypertensive effect of captopril combined with diuretics and beta-adrenergic blocking drugs in patients with resistant hypertension.

Authors:  T Forslund; F Fyhrquist; L Hortling
Journal:  Acta Med Scand       Date:  1983

9.  Effects of losartan on a background of hydrochlorothiazide in patients with hypertension.

Authors:  B A Soffer; J T Wright; J H Pratt; B Wiens; A I Goldberg; C S Sweet
Journal:  Hypertension       Date:  1995-07       Impact factor: 10.190

10.  Blood pressure and hypertension in middle-aged British men.

Authors:  A G Shaper; D Ashby; S J Pocock
Journal:  J Hypertens       Date:  1988-05       Impact factor: 4.844

View more
  2 in total

Review 1.  Review of resistant hypertension.

Authors:  C Venkata S Ram
Journal:  Curr Hypertens Rep       Date:  2006-10       Impact factor: 5.369

2.  Polytherapy with two or more antihypertensive drugs to lower blood pressure in elderly Ontarians. Room for improvement.

Authors:  Norman R C Campbell; Finlay A McAlister; Minh Duong-Hua; Karen Tu
Journal:  Can J Cardiol       Date:  2007-08       Impact factor: 5.223

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.